Amanote Research
Register
Sign In
Simvastatin as a Treatment for PAH
Advances in Pulmonary Hypertension
doi 10.21693/1933-088x-9.2.119
Full Text
Open PDF
Abstract
Available in
full text
Date
April 1, 2010
Authors
Unknown
Publisher
Pulmonary Hypertension Association
Related search
A New Day for PAH
Advances in Pulmonary Hypertension
A Classification System and Treatment Guidelines for PAH Associated With Congenital Heart Disease
Advances in Pulmonary Hypertension
Reply: Alopecia Areata Treatment With Simvastatin/Ezetimibe
Journal of the American Academy of Dermatology
Dermatology
ZNF542P Is a Pseudogene Associated With LDL Response to Simvastatin Treatment
Scientific Reports
Multidisciplinary
Pharmacokinetics of Ambrisentan, a Novel Drug for Treatment of Pulmonary Arterial Hypertension (PAH), in Japanese Subjects
Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
• Identifying the Complex Spectrum of Childhood PAH• Selecting Candidates for Aggressive Treatment
Advances in Pulmonary Hypertension
Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH
Advances in Pulmonary Hypertension
Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Simvastatin Plus Fenofibrate as a Fixed Dose Combination in the Treatment of Mixed Dyslipidemia in Greece: Budget Impact Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
